Systemic Treatments for Mesothelioma: Standard and Novel

Current Treatment Options in Oncology. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3. [Link] Kindler HL. Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu Abstract Systemic therapy is the only treatment option for the majority of mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and locally advanced disease often preclude surgery. For…

Read More

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

Clinical Cancer Research 13, 532-539, January 15, 2007. [Link] Eric K. Rowinsky1, Muralidhar Beeram1, Lisa A. Hammond1, Garry Schwartz2, Johann De Bono1, Baharam Forouzesh1, Quincy Chu1, Jane E. Latz3, Shengyan Hong3, William John3 and Binh Nguyen3 Authors’ Affiliations: 1 Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas; 2 Brooke Army Medical…

Read More

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma

Cancer. 2007 Jan 1;109(1):93-9. [Link] Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew’s Hospital, West Smithfield, London, UK. Abstract Background: Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome…

Read More

Epidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience

La Medicina del Lavoro. 2005 Jul-Aug;96(4):338-46. [Link] Nesti M, Marinaccio A, Gennaro V, Gorini G, Mirabelli D, Mensi C, Merler E, Montanaro F, Musti M, Pannelli F, Romanelli A, Tumino R; ReNaM Working Group. ISPESL – National Institute for occupational safety and prevention, Occupational Medicine Department, Epidemiology Unit Rome, Italy. Abstract Background: The Italian National…

Read More